Liso-cel continues to outperform standard of care in leukemia

Key takeaways:

Patients assigned liso-cel achieved longer median PFS and OS compared with standard of care.

ORR was significantly higher with liso-cel vs. standard of care.

CHICAGO — Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO Annual Meeting.

William G. Wierda

“Patients with CLL or small lymphocytic lymphoma who failed Bruton tyrosine kinase inhibitor and venetoclax have limited treatment options and poor prognoses,” according to William G. Wierda, MD, PhD, professor of medicine and center medical director in the department of leukemia at The University of Texas MD Anderson Cancer Center, and colleagues. “FDA approval of lisoc